Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32


Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage.

Gautier EL, Huby T, Witztum JL, Ouzilleau B, Miller ER, Saint-Charles F, Aucouturier P, Chapman MJ, Lesnik P.

Circulation. 2009 Apr 7;119(13):1795-804. doi: 10.1161/CIRCULATIONAHA.108.806158. Epub 2009 Mar 23.


Vulnerable plaque: scope of the problem.

Wilensky RL.

J Interv Cardiol. 2008 Dec;21(6):443-51. doi: 10.1111/j.1540-8183.2008.00401.x. Epub 2008 Oct 21. Review. No abstract available.


Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development.

Wilensky RL, Shi Y, Mohler ER 3rd, Hamamdzic D, Burgert ME, Li J, Postle A, Fenning RS, Bollinger JG, Hoffman BE, Pelchovitz DJ, Yang J, Mirabile RC, Webb CL, Zhang L, Zhang P, Gelb MH, Walker MC, Zalewski A, Macphee CH.

Nat Med. 2008 Oct;14(10):1059-66. doi: 10.1038/nm.1870. Epub 2008 Sep 21.


Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.

Serruys PW, García-García HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Bøtker HE, von Birgelen C, D'Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A; Integrated Biomarker and Imaging Study-2 Investigators..

Circulation. 2008 Sep 9;118(11):1172-82. doi: 10.1161/CIRCULATIONAHA.108.771899. Epub 2008 Sep 1.


Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention.

Anderson JL.

Am J Cardiol. 2008 Jun 16;101(12A):23F-33F. doi: 10.1016/j.amjcard.2008.04.015. Review.


The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.

Mohler ER 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A; Darapladib Investigators..

J Am Coll Cardiol. 2008 Apr 29;51(17):1632-41. doi: 10.1016/j.jacc.2007.11.079.


Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.

Robins SJ, Collins D, Nelson JJ, Bloomfield HE, Asztalos BF.

Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1172-8. doi: 10.1161/ATVBAHA.107.160739. Epub 2008 Mar 20.


Electrospray ionization mass spectrometry identifies substrates and products of lipoprotein-associated phospholipase A2 in oxidized human low density lipoprotein.

Davis B, Koster G, Douet LJ, Scigelova M, Woffendin G, Ward JM, Smith A, Humphries J, Burnand KG, Macphee CH, Postle AD.

J Biol Chem. 2008 Mar 7;283(10):6428-37. doi: 10.1074/jbc.M709970200. Epub 2007 Dec 29.


New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease.

Tsimikas S, Tsironis LD, Tselepis AD.

Arterioscler Thromb Vasc Biol. 2007 Oct;27(10):2094-9. Epub 2007 Jul 12. Review.


One-year cardiovascular event rates in outpatients with atherothrombosis.

Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, Röther J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S; REACH Registry Investigators..

JAMA. 2007 Mar 21;297(11):1197-206.


Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review.

Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F.

Mayo Clin Proc. 2007 Feb;82(2):159-65. Review.


Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis.

Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, Virmani R.

Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2523-9. Epub 2006 Sep 7.


Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease.

Kuvin JT, Dave DM, Sliney KA, Mooney P, Patel AR, Kimmelstiel CD, Karas RH.

Am J Cardiol. 2006 Sep 15;98(6):743-5. Epub 2006 Jul 26.


The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome.

Filippatos TD, Gazi IF, Liberopoulos EN, Athyros VG, Elisaf MS, Tselepis AD, Kiortsis DN.

Atherosclerosis. 2007 Aug;193(2):428-37. Epub 2006 Sep 5.


The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.

Muhlestein JB, May HT, Jensen JR, Horne BD, Lanman RB, Lavasani F, Wolfert RL, Pearson RR, Yannicelli HD, Anderson JL.

J Am Coll Cardiol. 2006 Jul 18;48(2):396-401. Epub 2006 May 24.


The immune response in atherosclerosis: a double-edged sword.

Hansson GK, Libby P.

Nat Rev Immunol. 2006 Jul;6(7):508-19. Epub 2006 Jun 16. Review.


Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses.

Shi Y, Zhang P, Zhang L, Osman H, Mohler ER 3rd, Macphee C, Zalewski A, Postle A, Wilensky RL.

Atherosclerosis. 2007 Mar;191(1):54-62. Epub 2006 Jun 9.


Pathology of the vulnerable plaque.

Virmani R, Burke AP, Farb A, Kolodgie FD.

J Am Coll Cardiol. 2006 Apr 18;47(8 Suppl):C13-8.


Supplemental Content

Support Center